Medications for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia

This is prospective randomized controlled study that will be conducted on men with BPH related LUTS amenable to medical treatment at Urology Department, Faculty of Medicine, Tanta University - Egypt after having their written informed consent.

The study is planned to include 150 patients in the study period from April 2024 to April 2025. Each enrolled patient must complete 12 weeks on medication with strict scheduled follow up.

Inclusion criteria

Sexually active patients with moderate BPH related LUTS amenable to medical treatment and completed 12 weeks follow up period.

Exclusion criteria

Indication for combined therapy in patients who have moderate to severe LUTS and an increased risk of disease progression (e.g. prostate volume more than 40 ml) or patients in need for anti-muscarinic for predominant storage symptoms.

Indication for surgical intervention:

Medically complicated patients:

Cardiac patients, unstable angina, recent myocardial infarction (<3months), hypotension.

Concomitant uses (potassium channel openers, alpha 1 blockers, nitrates). Stroke since less than 6 months.

Inclusion criteria

• Sexually active patients .
• ModerateBPH related LUTS ( bengin prostatic hyperplasia related lower urinary tract symtoms ) i.e: (international prostatic symptom score 8 to 19 : the higher score is the worse symptoms ).
• Patients accepted medical treatment and completed 12 weeks on medical treatment and strict follow up .

Exclusion criteria

• Indication for combined therapy as prostate size over 40 gm .
• Gross hematuria.
• Refractory urine retention .
• Bilateral hydro-ureteronephrosis or renal insufficiency secondary to bengin prostatic hyperplasia.
• Bladder diverticula or calculi .
• History of bladder or prostate cancer.
• Unwilling patients to medical therapy.
• History of pelvic surgery or urethral stricture.